Halozyme Therapeutics | HALO - Assets


Halozyme Therapeutics reported $2.22B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amarin USD 659.81M 10.31M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Baxter International USD 21.07B 21M Sep/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
MannKind USD 494.64M 82.94M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
United Therapeutics USD 7.35B 556.9M Sep/2025